Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvatinib + Everolimus
f. Nivolumab
g. Nivolumab + Cabozantinib
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab monotherapy
k. Pembrolizumab + Axitinib
l. Pembrolizumab + Lenvatinib
m. Sunitinib
n. Temsirolimus
o. Tivozanib
p. Other active systemic anti-cancer therapy
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Dacarbazine
e. Encorafenib AND Binimetinib
f. Ipilimumab
g. Ipilimumab AND Nivolumab
h. Nivolumab
i. Pembrolizumab
j. Trametinib
k. Vemurafenib
l. Vemurafenib AND Cobimetinib
m. Other active systemic anti-cancer therapy
n. Palliative care only
Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Encorafenib AND Binimetinib
e. Ipilimumab
f. Ipilimumab AND Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib AND Cobimetinib
l. Other active systemic anti-cancer therapy
m. Palliative care only
Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?